Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort.
BACKGROUND
We aimed to determine whether statin exposure in antiretroviral-treated individuals is associated with increases in hip circumference compared with HIV treatment without concomitant statin use.


METHODS
This was a prospective multicentre cohort study involving individuals who had received antiretroviral therapy for at least 40 weeks and who were enrolled in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort. There were 2,223 participants in the statin-unexposed group and 371 in the statin-exposed group. The main outcome measure was change in hip circumference at week 32.


RESULTS
The 32-week change in hip circumference in the statin-exposed group was 0.60 cm greater (95% confidence interval 0.11-1.10; P=0.02) than in the statin-unexposed group after adjustment for age, gender, race, baseline body mass index and thymidine analogue exposure.


CONCLUSIONS
Our findings support the hypothesis that statins might be beneficial in lipoatrophy. Given the limited treatment options for this important problem, further studies are needed to confirm this effect and to determine its clinical significance.
Brown
Todd T
TT
Division of Endocrinology and Metabolism, Johns Hopkins University, Baltimore, MD, USA. tbrown27@jhmi.edu
Smurzynski
Marlene
M
Wu
Kunling
K
Bosch
Ronald J
RJ
McComsey
Grace A
GA
D000273:Adipose Tissue / Q000187:drug effects*; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001823:Body Composition / Q000187:drug effects; D015331:Cohort Studies; D005260:Female; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy*; D006615:Hip; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D019380:Anti-HIV Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors